Tirzepatide Pen
£99.00
Sale price
£99.00
Regular price
Skip to product information
Weekly Injection
Tirzepatide Pen
Starting at £89 per vial with a
subscription plan
10mg Tirzepatide research solution, precisely dosed and independently verified by Janoshik Analytical. Dual GIP and GLP-1 receptor agonist studied extensively in published clinical trial settings. Designed for research purposes.
Meet the Tirzepatide Pen
-
Ready-to-use research solution
-
≥99% purity, third-party verified
-
Pharmaceutical grade research formulation
-
Free shipping on all UK orders
Pickup currently not available
Tirzepatide | A synthetic dual hormone receptor agonist targeting GIP and GLP-1 receptors simultaneously. Studied extensively in controlled clinical trial settings — including the landmark SURPASS and SURMOUNT trial programs — for its role in metabolic regulation, insulin sensitivity and adipose tissue research models.*
Our compounds are manufactured by Homopeptides and every batch is independently analysed by Janoshik Analytical before reaching you. Janoshik are one of the most respected third-party testing laboratories in the peptide research space — their verification gives you confidence in every order.
This compound has been reconstituted with bacteriostatic water (BAC water) and is supplied as a ready-to-use research solution. Store immediately upon receipt at 4°C in a refrigerator. Do not freeze. Keep away from direct light and heat sources. When stored correctly, BAC water reconstituted solutions typically remain stable for 4–6 weeks, though stability may vary depending on storage conditions and handling. Discard if any cloudiness, discolouration or particulate matter is observed. For laboratory and research purposes only.*
All orders are dispatched within 1–2 business days. Compounds are packaged with temperature-controlled materials to maintain integrity during transit. Free shipping on all UK orders.
Featured reviews
Compounds trusted by researchers worldwide
Vytol compounds used by over 10,000 researchers across 50+ countries
Month 0
Month 3
"Exceptional quality and purity. The results speak for themselves in our research applications."
Sarah Mitchell
Verified review
Month 0
Month 6
"Consistent results across multiple trials. Vytol has become our trusted supplier for peptide research."
Prof. James Chen
Verified review
Month 0
Month 4
"Outstanding customer service and product documentation. Makes my research workflow seamless."
Dr. Emily Rodriguez
Verified review
Compounds built for
precision
Body weight reduction recorded in the SURMOUNT-1 Phase 3 trial over 72 weeks.
Of participants on tirzepatide 10mg and 15mg achieved at least 5% body weight reduction.*
*Based on published peer-reviewed in-vitro research. For research purposes only.
*Jastreboff AM et al. 'Tirzepatide Once Weekly for the Treatment of Obesity.' N Engl J Med. 2022;387:205–216. SURMOUNT-1 Phase 3 clinical trial, Eli Lilly. For research purposes only. Not for human use. Individual results not implied or guaranteed.
